This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RAIN Rain Oncology (RAIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesInsider TradesTrendsBuy This Stock About Rain Oncology Stock (NASDAQ:RAIN) 30 days 90 days 365 days Advanced Chart Get Rain Oncology alerts:Sign Up Key Stats Today's Range$3.18▼$3.9050-Day Range$1.20▼$1.2452-Week Range$0.82▼$11.32Volume113,185 shsAverage Volume32,376 shsMarket Capitalization$19.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.Read More… Receive RAIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address RAIN Stock News HeadlinesToronto runners brave rain to raise roughly $23,000 for cancer fightMarch 15, 2025 | msn.com13-year-old rain cancer survivor calls out Democrats: ‘Stop being mean to Trump’March 8, 2025 | msn.comTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has hit extremes, it’s spelled doom for stocks — and soaring gains for gold. Today, the Indicator is flashing a historic all-time high. Meanwhile, Buffett is quietly hoarding $325 billion in cash — and insiders believe he’s about to make a gold move big enough to shock Wall Street. Garrett Goggin has the names of 4 companies likely to benefit — if you move fast. April 30, 2025 | Golden Portfolio (Ad)Brain cancer: Recognising tumour symptoms, risk factors and seeking treatmentNovember 24, 2024 | msn.comNewfoundland man electrocuted by downed power line, two women injuredNovember 11, 2024 | msn.comKing Charles III and Kate attend remembrance events as both slowly return to dutyNovember 11, 2024 | msn.comPrince William describes family's ‘brutal’ year as wife and father faced cancer treatmentNovember 8, 2024 | msn.comThe Eras Tour kept me going during my breast cancer treatmentNovember 8, 2024 | theglobeandmail.comSee More Headlines RAIN Stock Analysis - Frequently Asked Questions How were Rain Oncology's earnings last quarter? Rain Oncology Inc. (NASDAQ:RAIN) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.06. When did Rain Oncology IPO? Rain Oncology (RAIN) raised $126 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO. What other stocks do shareholders of Rain Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rain Oncology investors own include CRISPR Therapeutics (CRSP), Meta Platforms (META), UiPath (PATH), Recursion Pharmaceuticals (RXRX), Alibaba Group (BABA), NVIDIA (NVDA) and Company Calendar Last Earnings11/10/2021Today4/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:RAIN CIK1724979 Webwww.rainthera.com Phone510-953-5559FaxN/AEmployees63Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.10 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-9.51% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.48 per share Price / Cash Flow7.41 Book Value($0.69) per share Price / Book-5.17Miscellaneous Outstanding Shares5,540,000Free Float4,574,000Market Cap$19.78 million OptionableNo Data Beta-0.11 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:RAIN) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Silent Heist Draining Your Retirement SavingsU.S. Debt Crisis - A Silent Heist of Your Retirement Savings Americans are losing wealth daily and don't ev...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rain Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rain Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.